Reuters logo
BRIEF-Synergy Pharmaceuticals says to present positive TRULANCE phase 3 data
May 9, 2017 / 4:33 PM / 4 months ago

BRIEF-Synergy Pharmaceuticals says to present positive TRULANCE phase 3 data

May 9 (Reuters) - Synergy Pharmaceuticals Inc:

* To present positive TRULANCE phase 3 data

* TRULANCE 3 mg,6 mg doses met primary endpoint

* TRULANCE 3 mg,6 mg doses showed statistical significance in percent of patients who were overall responders compared to placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below